26 results
6-K
EX-99.1
OBSVF
ObsEva SA
30 Mar 18
Current report (foreign)
12:00am
: IMPLANT3USInitiation 4Q 2018 EU Phase 2a Preterm Labor: PROLONGInterim DataWorldwide Late 2018 ** Patient recruitment completed *** Week10 pregnancy … trial EU/US patient enrollment4Q2017 NOLASIBAN (IVF): Completed IMPLANT2 trial recruitment 3Q2017 OBE022 (Preterm labor): Initiate Phase 2a
6-K
EX-99.3
OBSVF
ObsEva SA
9 May 19
Index to Unaudited Condensed Consolidated Financial Statements
6:05am
quarter of 2019, ObsEva expects to complete patient recruitment in the IMPLANT 4 trial of nolasiban, and to report primary endpoint results (10-week … recruitment in the PRIMROSE 1 trial of linzagolix for the treatment of uterine fibroids, and to report 6-month primary endpoint data in the first
6-K
EX-99.2
OBSVF
ObsEva SA
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
and in Europe, completed patient recruitment in December 2018, and the PRIMROSE 1 trial, conducted in the U.S., completed patient recruitment in July … , or the IMPLANT 4 trial. In June 2019, we announced completion of patient recruitment in the IMPLANT 4 trial. In addition, we announced the clearance of our
6-K
OBSVF
ObsEva SA
19 Jun 19
Current report (foreign)
4:30pm
following IVF. On June 4, 2019, ObsEva announced completion of patient recruitment in the trial; primary end point results are anticipated
6-K
EX-99.3
OBSVF
ObsEva SA
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
, 75mg once daily without low-dose hormonal add-back therapy (ABT) and 200mg once daily with ABT.
Completed patient recruitment in PRIMROSE 1, the U.S
6-K
elp02gxazr1uz9u sh8
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
EX-99.2
tb4h6mkefncz9xh
18 Jun 18
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS
9:17am
6-K
EX-99.2
i09i3
9 May 19
Index to Unaudited Condensed Consolidated Financial Statements
6:05am
6-K
EX-99.2
0csok2t lzp
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.2
kw1m3gzok3999grkt0q
16 May 18
Index to Unaudited Consolidated Interim Financial Statements
4:56pm
6-K
EX-99.2
lycm0c0trvhjl1x
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
eu36 6yhm5ekokgxry
7 Aug 19
Current report (foreign)
7:21am
6-K
EX-99.2
sn0m4166
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
DRS
EX-10
nyy7i4od7oc78
14 Oct 16
Draft registration statement
12:00am
F-1
EX-10.3
pn6ggav4
30 Dec 16
Registration statement (foreign)
12:00am